期刊
CANCER CELL INTERNATIONAL
卷 12, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1475-2867-12-27
关键词
Oncolytic virus; HNSCC; Radiotherapy; Vascular disrupting
类别
资金
- Canadian Institutes of Health Research
- Dr. Mariano Elia Chair in Head and Neck Cancer Research
- Terry Fox Foundation Strategic Training Initiative for Excellence in Radiation Research for the 21st Century (EIRR21), at the Canadian Institutes of Health Research (CIHR)
- Campbell Family Institute for Cancer Research
- Ministry of Health and Long-Term Planning
Background: Head and neck squamous cell carcinoma (HNSCC) is the 5th most common cancer worldwide. Locally advanced HNSCC are treated with either radiation or chemo-radiotherapy, but still associated with high mortality rate, underscoring the need to develop novel therapies. Oncolytic viruses have been garnering increasing interest as anti-cancer agents due to their preferential killing of transformed cells. In this study, we evaluated the therapeutic potential of mutant vesicular stomatitis virus (VSV Delta 51) against the human hypopharyngeal FaDu tumour model in vitro and in vivo. Results: Our data demonstrated high toxicity of the virus against FaDu cells in vitro, which was associated with induction of apoptosis. In vivo, systemic injection of 1 x 10(9) pfu had minimal effect on tumour growth; however, when combined with two doses of ionizing radiation (IR; 5 Gy each) or a single injection of the vascular disrupting agent (ZD6126), the virus exhibited profound suppression of tumour growth, which translated to a prolonged survival in the treated mice. Concordantly, VSV Delta 51 combined with ZD6126 led to a significant increase in viral replication in these tumours. Conclusions: Our data suggest that the combinations of VSV Delta 51 with either IR or ZD6126 are potentially novel therapeutic opportunities for HNSCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据